AzTrials
AzTrials

Pancreatic CanceriCaRe2NCT02012699

Integrated Cancer Repository for Cancer Research

An observational study of Pancreatic Cancer and Thyroid Cancer, run by University of Nebraska at 42 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. Read more about this study

Who is it for?
Ages 19 to 110 yearsHealthy volunteers can take part
Conditions the study is for
Pancreatic Cancer, Thyroid Cancer, Lung Cancer
How many people
999,999 participants
Where
42 sitesUnited States
Study dates
1 Nov 2013to Dec 2099
How long will I take part?
80 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 to 110 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Any individual who meets the eligibility criteria will be invited to participate in iCaRe2.

Who may be able to join

  • Diagnosis/history of cancer
  • Risk for developing cancer or suspicious clinical findings
  • No history of cancer (normal control registry)
  • Able to provide informed consent
  • 19 years of age or older
  • English or Spanish speaking individuals

Who cannot join

  • Unable to provide informed consent because of cognitive impairment
  • Non-English or non-Spanish speaking individuals

Trial locations and contacts

42 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Artem Pachikov contact

402-559-0568

artem.pachikov@unmc.edu

42 sites in 1 country

United States42 sites, 42 recruiting

  • Riverwood Healthcare Center

    Aitkin, Minnesota, 56431

    Alaina Wadzink, 218-786-1018, alaina.wadzink@essentiahealth.org

    Bret Friday, MD, PhD

    Recruiting

  • Aultman Alliance Community Hospital

    Alliance, Ohio, 44601

    Carla Larch, 330-363-7412, carla.larch@aultman.com

    Steven Eric Olyejar, MD

    Recruiting

  • Rush-Copley Cancer Care Center

    Aurora, Illinois, 60504

    Joseph Meschi, MD, joseph.meschi@rushcopley.com

    Amanda Baker, CCRP, 630-978-6212, amanda.baker@rushcopley.com

    Recruiting

  • Bozeman Health Deaconess Hospital

    Bozeman, Montana, 59715

    Adam Gott, 406-414-3745, agott@bozemanhealth.org

    Justin Thomas, MD

    Recruiting

  • Essentia Health-St. Joseph's Medical Center

    Brainerd, Minnesota, 56401

    Alaina Wadzink, 218-786-1018, alaina.wadzink@essentiahealth.org

    Bret Friday, MD

    Recruiting

  • Aultman Hospital

    Canton, Ohio, 44710

    Carla Larch, 330-363-7412, carla.larch@aultman.com

    Steven Eric Olyejar, MD

    Recruiting

  • Methodist Jennie Edmundson Hospital

    Council Bluffs, Iowa, 51503

    Michael Zlomke, MD, 712-396-4117

    Tammy Johnson, CBPN, tammy.johnson@nmhs.org

    Recruiting

  • Florida Hospital Memorial Medical Center

    Daytona Beach, Florida, 32117

    Sandy Allten, RN, 386-231-4023, sandra.allten@fhmmc.org

    Erik Harris, MD

    Recruiting

  • Florida Hospital DeLand

    DeLand, Florida, 32720

    Sandra Allten, RN,OCN,CCRP, 386-231-3267, sandra.allten@fhmmc.org

    Erik Harris, MD

    Recruiting

  • Essentia Health - Duluth Clinic

    Duluth, Minnesota, 55805

    Alaina Wadzink, 218-786-1018, alaina.wadzink@essentiahealth.org

    Bret Friday, MD, PhD

    Recruiting

  • St. Luke's Hospital of Duluth

    Duluth, Minnesota, 55805

    Cade McDonald, 218-249-5002, cade.mcdonald@aspirus.org

    Anne Silva-Benedict, MD

    Recruiting

  • Essentia Health

    Fargo, North Dakota, 58103

    Alaina Wadzink, 218-786-1018, alaina.wadzink@essentiahealth.org

    Tammie Mlodozyniec, tammie.mlodozyniec@essentiahealth.org

    Recruiting

  • Cape Fear Valley Health System

    Fayetteville, North Carolina, 28304

    Kenneth Manning, MD

    Rebekah Bullard, 910-615-5603, rbullard@capefearvalley.com

    Recruiting

  • Lake Region Healthcare

    Fergus Falls, Minnesota, 56537

    Alaina Wadzink, 218-786-1018, alaina.wadzink@essentiahealth.org

    Bret Friday, MD

    Recruiting

  • Parkview Research Center

    Fort Wayne, Indiana, 46845

    Ellie Ross, ellie.ross@parkview.com

    Brian Johnson, MD

    Recruiting

  • C.R. Wood Cancer Center, Glens Falls Hospital

    Glens Falls, New York, 12801

    Misty LaCross DeCaro, RN-BSN, 518-926-6529, mjlacross@glensfallshosp.org

    Aqeel Gillani, MD, 518-926-6701

    Recruiting

  • Bellin Memorial Hospital

    Green Bay, Wisconsin, 54305

    Abigail Hecker, 920-430-4660, abigail.hecker@bellin.org

    Seth Joppe, 920-430-4660, seth.joppe@bellin.org

    Recruiting

  • Advent Health

    Greenwood Village, Colorado, 80111

    Roseann Johnson, 303-765-6840, roseann.johnson@adventhealth.com

    Mohammed Salhab, MD

    Recruiting

  • Mary Lanning Healthcare, Morrison Cancer Center

    Hastings, Nebraska, 68901

    Joan Meese, 402-460-5899, joan.meese@marylanning.org

    Recruiting

  • Holyoke Medical Center

    Holyoke, Massachusetts, 01040

    Lynn Downey, RHIT, CTR, 413-534-2500, downey_lynn@holyokehealth.com

    Zubeena Mateen, MD

    Recruiting

  • Saint Luke's Cancer Institute, East

    Kansas City, Missouri, 64086

    Ragan Verelst, 816-287-6057, rverelst@saint-lukes.org

    Addison Tolentino, MD

    Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri, 64111

    Ragan Verelst, 816-287-6057, rverelst@saint-lukes.org

    Addison Tolentino, MD

    Recruiting

  • Saint Luke's Cancer Institute, Kansas City North

    Kansas City, Missouri, 64118

    Ragan Verelst, 816-287-6057, rverelst@saint-lukes.org

    Addison Tolentino, MD

    Recruiting

  • Saint Luke's Cancer Institute, Liberty

    Liberty, Missouri, 64068

    Ragan Verelst, 816-287-6057, rverelst@saint-lukes.org

    Addison Tolentino, MD

    Recruiting

  • Hartford HealthCare Cancer Institute at Manchester Medical Hospital

    Manchester, Connecticut, 06040

    Amanda Doughty, 860-310-6475, amanda.doughty@hhchealth.org

    Leslie Juliani, BSN, RN, OCN, CBCN

    Recruiting

  • Trinity Hospital Cancer Care Center

    Minot, North Dakota, 58701

    Trish Miller, 701-418-8348, trish.miller@trinityhealth.org

    Marianna Jimenez, marianna.jimenez@trinityhealth.org

    Recruiting

  • Faith Regional Health Services, Carson Cancer Center

    Norfolk, Nebraska, 68701

    Cynthia Montgomery, RN, 402-644-7534, cmontgome@frhs.org

    Rahib C Fahed, MD

    Recruiting

  • North Kansas City Hospital

    North Kansas City, Missouri, 64116

    Magdalena Kosinska, 816-691-5195, magdalena.kosinska@nkch.org

    John Park, MD

    Recruiting

  • Great Plains Regional Medical Center

    North Platte, Nebraska, 69101

    Rebecca Dotson, 308-696-7386, dotsonr@gphealth.org

    Kartik Anand, MD

    Recruiting

  • Methodist Estabrook Cancer Center

    Omaha, Nebraska, 68114

    Russell Smith, MD

    Liza Brandes, 402-354-5892, liza.brandes@nmhs.org

    Recruiting

  • Nebraska Methodist Health System

    Omaha, Nebraska, 68114

    Kathryn Bartz, 402-354-7939, kathryn.bartz@nmhs.org

    Aru Panwar, MD

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Kurt Fisher, MD, PhD, 402-559-9025, kfisher@unmc.edu

    Kurt Fisher, MD, PhD

    Recruiting

  • Florida Hospital FISH

    Orange City, Florida, 32763

    Sandy Allten, RN, 386-231-4023, sandra.allten@fhmmc.org

    Erik Harris, MD

    Recruiting

  • Saint Luke's Cancer Instititute - South

    Overland Park, Kansas, 66213

    Ragan Verelst, 816-287-6057, rverelst@saint-lukes.org

    Amy Miller, amymiller@sait-lukes.org

    Recruiting

  • Florida Hospital Flagler

    Palm Coast, Florida, 32164

    Sandy Allten, RN, 386-231-4023, sandra.allten@fhmmc.org

    Erik Harris, MD

    Recruiting

  • Northwest Hospital

    Randallstown, Maryland, 21133

    Judy Bosley, 410-871-7450, jbosley@lifebridgehealth.org

    Qiwei Gai, MD

    Recruiting

  • Heartland Regional Medical Center dba Mosaic Life Care

    Saint Joseph, Missouri, 64507

    Molly Kidwell, 816-271-7654, molly.kidwell@mymlc.com

    Juliet Gyamfua Appiah, MD

    Recruiting

  • Tallahassee Memorial Hospital

    Tallahassee, Florida, 32308

    Justin Lee, 701-857-3174, justin.lee2@tmh.org

    Recruiting

  • Faxton St. Luke's Healthcare, Mohawk Valley

    Utica, New York, 13501

    Kristen Crowder, BSN, RN, OCN, 315-624-4831, kcrowder@mvhealthsystem.org

    Atul Butala, MD

    Recruiting

  • Covenant Medical Center, Inc

    Waterloo, Iowa, 50702

    Karrie Cheeseman, BSN, RN, 319-272-2388, karrie.mccagecheeseman@mercyhealth.com

    Mukund Nadipuram, MD

    Recruiting

  • William E. Kahlert Regional Cancer Center

    Westminster, Maryland, 21157

    Judy Bosley, 410-871-7450, jbosley@lifebridgehealth.org

    Melissa Loomis

    Recruiting

  • Rush-Copley Healthcare Center

    Yorkville, Illinois, 60560

    Amanda Baker, CCRP, 630-978-6212, amanda.baker@rushcopley.com

    Joseph T Meschi, MD

    Recruiting

Other trials in United States

About this study

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Read the detailed description

The integrated Cancer Repository for Cancer Research (iCaRe2 http://icare2.unmc.edu) is a unique sociotechnical resource for the collection and management of cancer and health-related data at the Fred \& Pamela Buffett Cancer Center at University of Nebraska Medical Center (UNMC). The iCaRe2 is a multi-center, semantically interoperable and easily customizable cancer data resource, which is aimed at collecting, managing, mining and sharing the comprehensive, multi-dimensional cancer-related data on cancer patients and biospecimens (such as tumor specimens, germ line DNA, serum, urine, and plasma) collected from those individuals.

The iCaRe2 has been developed as an expansion of the biocomputing framework that initially included four multi-center collaborative registries: Pancreatic Cancer Collaborative Registry (PCCR), Breast Cancer Collaborative Registry (BCCR), Thyroid Cancer Collaborative Registry (TCCR), and Great Plains Health Informatics Database (GPHID; to enroll subjects with no history of cancer diagnosis at time of enrollment). The repository now includes: Thoracic Oncology Collaborative Registry (TOCR), GenitoUrinary Cancer Collaborative Registry (GUCARE), Head and Neck Cancer Collaborative Registry (HNCCR), Gastrointestinal \& Abdominal Cavity Cancer Collaborative Registry (GACCaRe), Central Nervous System Tumor Collaborative Registry (CTCR), Leukemia and Myeloid Neoplasm Registry (LEMN) , Gynecological Cancer Collaborative Registry (GCCR), Sarcoma Collaborative Registry (SARCR), Melanoma Collaborative Registry (MELCR), Plasma Cell Dyscrasias Collaborative Registry (PDCR), Neuroendocrine Collaborative Registry (NETR), Non-Melanoma Skin Cancer Registry (NMSC) and Auxiliary Cancer Registry (ACR).

The iCaRe2 group elected to use a "confederation model", as opposed to a traditional registry or network model. The major advantages of a confederation model include the flexibility to use selected Centers for different research projects based on a Center's resources and expertise and the ability to have different strategies to address various research questions. A web-based registry iCaRe2 was developed and made available to any Center to participate in data collection and storage of cancer related data. The iCaRe2 provides a HIPAA compliant, secure, efficient and user-friendly mechanism for data and validation; utilization of standard vocabulary and data elements; and ad-hoc data reporting capabilities. The iCaRe2 serves as a collaboration platform for studies (including clinical trials) performed in centers with expertise in cancer biology, pathology, epidemiology, genetics, early detection, and patient care.

Keywords
Pancreatic Cancer, Thyroid Cancer, Esophageal cancer, Thymus cancer, Pancreatic tumor, Esophageal tumor, Thymus tumor, Thyroid Tumor, Thyroid Nodule, Lung Tumor, Breast Cancer, Neuroendocrine tumor, Plasma Cell Dyscrasia, Healthy Control
Medical subject headings
Pancreatic Neoplasms, Thyroid Neoplasms, Lung Neoplasms, Esophageal Neoplasms, Thymus Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Gastrointestinal Stromal Tumors

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development and Implementation of a Web-based Cancer Collaborative Registry

    This is a registry that will continue to accrue participants indefinitely.

    Measured: 86 years

Secondary outcomes (1)

  1. Procurement and Banking of Excess Biological Material for Future Analysis

    This is a registry that will continue to accrue participants indefinitely.

    Measured: 86 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2013 (estimated)
  2. Study start1 Nov 2013
  3. Primary completionDec 2099 (estimated)
  4. Study completionDec 2099 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
999,999 participants (estimated)
Target duration
80 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT02012699
Sponsor's protocol ID
0253-13-EP
Acronym
iCaRe2
Status last verified
Jun 2025
First submitted
2 Dec 2013
Last updated
29 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All data and/or specimen request have to be made to the Principal Investigator of the center and follow the Human Subject Protection guidelines and policy.

Questions about this trial

What is this clinical trial studying?

An observational study of Pancreatic Cancer and Thyroid Cancer, run by University of Nebraska at 42 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 42 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Artem Pachikov (402-559-0568, artem.pachikov@unmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Development and Implementation of a Web-based Cancer Collaborative Registry (time frame: 86 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02012699.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026; AzTrials last refreshed its copy on 26 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in